Skip to content
91 (11) 32911528 , 32911529 |solution@brawnbiotech.com
Brawn Biotech Ltd. Logo Brawn Biotech Ltd. Logo
  • Home
  • About Us
    • Company Profile
    • MOA
    • Board of Directors and Senior Management Personnel
    • Vision
    • Business Alliance
    • Operations
      • Domestic Operations
      • International Operations
  • Products
    • Products
  • Contact Us
  • Investors
    • Composition of Board of Directors
    • Shareholding Pattern
    • Policies
      • Policies
      • Code for Prohibition of Insider Trading Code
      • Familiarization Programme For Independent Directors
      • Terms and Conditions for Appointment of Independent Directors
    • Integrated Filing
    • Newspaper Publications
    • Notice of Information
      • Board Meeting
      • General Meeting
    • Annual Report
    • Results Outcome
    • ISR and Nomination form
      • Shareholders Form
    • RTA and Compliance
    • Shareholders Information
    • Unpaid Unclaimed Dividend Account
    • Investor Contacts
    • Stock Performance
      • Listing Information
      • Stock History
    • Shareholder’s Query
    • FAQ
    • Closure Of Trading Window
  • AGM Meetings
    • AGM Meetings 23-24
  • Blog
  • Home
  • About Us
    • Company Profile
    • MOA
    • Board of Directors and Senior Management Personnel
    • Vision
    • Business Alliance
    • Operations
      • Domestic Operations
      • International Operations
  • Products
    • Products
  • Contact Us
  • Investors
    • Composition of Board of Directors
    • Shareholding Pattern
    • Policies
      • Policies
      • Code for Prohibition of Insider Trading Code
      • Familiarization Programme For Independent Directors
      • Terms and Conditions for Appointment of Independent Directors
    • Integrated Filing
    • Newspaper Publications
    • Notice of Information
      • Board Meeting
      • General Meeting
    • Annual Report
    • Results Outcome
    • ISR and Nomination form
      • Shareholders Form
    • RTA and Compliance
    • Shareholders Information
    • Unpaid Unclaimed Dividend Account
    • Investor Contacts
    • Stock Performance
      • Listing Information
      • Stock History
    • Shareholder’s Query
    • FAQ
    • Closure Of Trading Window
  • AGM Meetings
    • AGM Meetings 23-24
  • Blog

UNPAID UNCLAIMED DIVIDEND ACCOUNT

Home/UNPAID UNCLAIMED DIVIDEND ACCOUNT
UNPAID UNCLAIMED DIVIDEND ACCOUNTpramod Kumar2024-04-01T13:35:23+05:30

2017-18

Unpaid_2018

2016-17

Unpaid_2017

Important Links

  • About Us
  • FAQ
  • Products

Contact Us

  • Email
    solution@brawnbiotech.com
  • Phone
    011- 29815331

Address

Brawn Biotech Limited
C-64, Lajpat Nagar - 1, New Delhi,
Delhi - 110024

Web: https://brawnbiotech.com/

© Copyright | Brawn Biotech Ltd | All Rights Reserved
Facebook

IMPORTANT ANNOUNCEMENT

To,

The Shareholders/ Promoters,

 

Pursuant to SEBI Circular No. SEDI/HO/MIRSD-PoD/P/CIR/2025/97, dated July 02, 2025, the Company is pleased to offer one time special window for physical shareholders to submit re-lodgement requests for the transfer of shares. The Special Window will be open from July 07, 2025 to January 06, 2026 and is applicable to cases where original share transfer requests were lodged prior to April 01, 2019 and were returned/ unattended or rejected due to deficiencies in documentation, process or any other reason. The shares re-lodged for transfer will be processed only in dematerialized form during this window. Eligible shareholders may submit their transfer requests along with the requisite documents to the Company’s Registrar and Share Transfer Agent (RTA) at RCMC Share Registry Pvt. Ltd. , B-25/1, 1st Floor, Okhla Industrial Area, Phase II, New Delhi, 110020, India.

UPDATE KYC AND CONVERT PHYSICAL SHARES INTO DEMAT MODE

The Shareholders who are holding shares in Physical form are requested to  update their KYC and also requested to convert their physical share Certificates in to dematerialized form ( electronic Form).Further pursuant to SEBI Circular No. SEBI/Cir/ISD/3/2011 dated June 17, 2011 in order to promote dematerialization of securities, it is mandatory for the Company to achieve 100% of promoter’s and promoter group’s shareholding in dematerialized form, thereby they are requested to convert their holdings in dematerialized form on priority basis.

 

 Thanks

 Brawn Biotech Limited.

This will close in 0 seconds

Go to Top